PolyPid Total Liabilities 2019-2025 | PYPD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

PolyPid total liabilities from 2019 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

PolyPid total liabilities from 2019 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$81.3B
Zoetis (ZTS)	$67.2B
Daiichi Sankyo, - (DSNKY)	$46.3B
Takeda Pharmaceutical (TAK)	$45.6B
BeOne Medicines - (ONC)	$33.5B
Sandoz Group AG (SDZNY)	$26B
Summit Therapeutics (SMMT)	$19.9B
Merck (MKKGY)	$16.9B
Shionogi (SGIOY)	$14.3B
United Therapeutics (UTHR)	$13.4B
Neurocrine Biosciences (NBIX)	$13.3B
Orion OYJ (ORINY)	$11.4B
IPSEN (IPSEY)	$10.8B
Stevanato Group S.p.A (STVN)	$7.7B
Corcept Therapeutics (CORT)	$7.2B
Grifols, S.A (GRFS)	$7.2B
Ionis Pharmaceuticals (IONS)	$6.6B
Madrigal Pharmaceuticals (MDGL)	$6.5B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.2B
Hypermarcas (HYPMY)	$3B
Crinetics Pharmaceuticals (CRNX)	$2.7B
Catalyst Pharmaceuticals (CPRX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2B
Ocular Therapeutix (OCUL)	$1.9B
Endo (NDOI)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.7B